On November 30, 2018, Global Affairs Canada issued a news release announcing the signing of the Canada-United States-Mexico Agreement (CUSMA or USMCA), a new agreement to modernize the North American Free Trade Agreement between Canada, the United States, and Mexico. The changes relating to intellectual property are particularly notable as they modify the landscape for pharmaceuticals, and for patent, copyright and trademark owners. The potential impact on Canada's intellectual property laws was previously reported here, including the requirement to provide a data protection term (market exclusivity) for biologics of at least ten years from the date of first marketing approval. Canada must implement this change within five years of the date the CUSMA enters into force.
Related Publications & Articles
-
CIPO expected to resume patent granting on August 20
According to CIPO’s updated roadmap, patent granting should resume on August 20, 2024.Read More -
Manitoba last province to introduce Biosimilars Initiative, while Ontario adds four drugs to its Biosimilar Policy
Manitoba has implemented a Biosimilars Initiative effective August 1, 2024.Read More -
Release of Statistical Report 2023/2024 for PMNOC Regulations, data protection and CSPs
On August 12, 2024, the Office of Patented Medicines and Liaison of Health Canada released its Statistical Report 2023/2024 for the Patented Medicines (Notice of Compliance) Regulations, Data Protecti...Read More